Visa buys BioCatch for $2.4 billion
Visa is buying behavioral-fraud specialist BioCatch for $2.4 billion in cash, a deal that pushes the card network deeper into bank-side security as artificial intelligence turbocharges account takeovers and scams. The acquisition gives Visa a tool designed to flag fraud before a payment is authorized, not just after a transaction hits the network.
The purchase is strategically important because many of the fastest-growing fraud types now bypass traditional card controls. BioCatch’s software watches the banking session itself — the login, transfer request and account application — and scores thousands of signals in real time, including keystrokes, touch behavior, device handling and network data.
Visa said BioCatch protects 1.8 billion devices and 760 million users, serves more than 350 banking clients in 21 countries and analyzes 19 billion user sessions a month. The company says the models help detect account takeovers, scams, money mules and application fraud, categories that can be harder to stop because the real account holder may be the one authorizing the payment.
The deal also extends Visa’s recent push into AI-powered fraud defenses. It bought transaction-monitoring company Featurespace in late 2024, giving it coverage at a different point in the payment chain. Together, the two businesses let Visa monitor both the person generating the payment and the payment event itself.
For investors, the transaction reinforces Visa’s push to monetize fraud prevention and other value-added services as payments become more digital and more vulnerable to AI-enabled attacks. Visa said it has invested more than $13 billion in technology and infrastructure over the past five years to harden the network and reduce fraud, suggesting the company is still willing to spend heavily to protect its franchise and deepen relationships with banks.
The price also shows how quickly the asset has appreciated. Permira bought a majority stake in BioCatch in 2024 at a $1.3 billion valuation; Visa is paying about 1.8 times that level. BioCatch has since expanded to more than 350 financial-institution clients from more than 200 and nearly doubled the number of users it covers.
Visa shares were little changed after the announcement, with the stock trading around $370 and above both its 50-day and 200-day moving averages. Mastercard and PayPal, meanwhile, remain exposed to the same fraud pressure that is driving the deal, though PayPal’s stock has already been battered by broader concerns about growth and risk controls.
The acquisition is expected to close by the end of Visa’s fiscal second quarter of 2027, pending regulatory approvals. The key test for banks will be how quickly BioCatch’s session-scoring tools are integrated into Visa’s fraud products and whether the payment giant can turn tighter security into a bigger recurring revenue stream.
| Entity | Gains | Losses |
|---|---|---|
| Visa | ▲Deeper fraud toolkit | ▼Higher integration risk |
| BioCatch | ▲Broader distribution | ▼Loss of independence |
| Banks | ▲Earlier scam detection | ▼New vendor dependence |
| Fraudsters | ▲Less room to operate | ▼Stronger behavioral screening |